DOCSLIB.ORG

Oxford® Policy Update Bulletin: October 2015 Oxford

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Oxford® Policy Update Bulletin: October 2015 Oxford Oxford October 2015 policy update bulletin Medical & Administrative Policy Updates UnitedHealthcare respects the expertise of the physicians, health care professionals, and their staff who participate in our network. Our goal is to support you and your patients in making the most informed decisions regarding the choice of quality and cost-effective care, and to support practice staff with a simple and predictable administrative experience. The Policy Update Bulletin was developed to share important information regarding Oxford® Medical and Administrative Policy updates.* *Where information in this bulletin conflicts with applicable state and/or federal law, Oxford® follows such applicable federal and/or state law Oxford Oxford® Medical and Administrative Policy Updates Overview This bulletin provides complete details on Oxford® Medical and Policy Update Classifications Administrative Policy updates. The appearance of a service or New procedure in this bulletin indicates only that Oxford® has recently New clinical coverage criteria and/or documentation review requirements adopted a new policy and/or updated, revised, replaced or have been adopted for a service, procedure, test, or device retired an existing policy; it does not imply that Oxford® provides Updated coverage for the service or procedure. In the event of an An existing policy has been reviewed and changes have not been made inconsistency or conflict between the information provided in this to the clinical coverage criteria or documentation review requirements; bulletin and the posted policy, the provisions of the posted policy however, items such as the clinical evidence, FDA information, and/or will prevail. Note that most benefit plan documents exclude from list(s) of applicable codes may have been updated benefit coverage health services identified as investigational or unproven/not medically necessary. Physicians and other health Revised care professionals may not seek or collect payment from a An existing policy has been reviewed and revisions have been made to member for services not covered by the applicable benefit plan the clinical coverage criteria and/or documentation review requirements unless first obtaining the member’s written consent, Replaced acknowledging that the service is not covered by the benefit plan An existing policy has been replaced with a new or different policy and that they will be billed directly for the service. Retired A complete library of Oxford® Medical and Administrative The procedural codes and/or services previously outlined in the policy are Policies is available at OxfordHealth.com > Providers > no longer being managed or are considered to be proven/medically Tools & Resources > Medical Information > Medical and necessary and are therefore not excluded as unproven/not medically Administrative Policies. necessary services, unless coverage guidelines or criteria are otherwise documented in another policy Note: The absence of a policy does not automatically indicate or imply Tips for using the Policy Update Bulletin: coverage. As always, coverage for a service or procedure must be From the table of contents, click the policy title to be determined in accordance with the member’s benefit plan and any directed to the corresponding policy update summary. applicable federal or state regulatory requirements. Additionally, UnitedHealthcare reserves the right to review the clinical evidence From the policy updates table, click the policy title to view a supporting the safety and effectiveness of a medical technology prior to complete copy of a new, updated, or revised policy. rendering a coverage determination. 2 Oxford® Policy Update Bulletin: October 2015 Oxford Oxford® Medical and Administrative Policy Updates In This Issue Clinical Policy Updates Page NEW Follicle Stimulating Hormone (FSH) Gonadotropins - Effective Nov. 1, 2015 ............................................................................................................. 7 Human Menopausal Gonadotropins (hMG) - Effective Nov. 1, 2015 ......................................................................................................................... 9 UPDATED 17-Alpha-Hydroxypro-gesterone Caproate (Makena and 17P) - Effective Nov. 1, 2015 ............................................................................................ 12 Alemtuzumab - Effective Oct. 1, 2015 ............................................................................................................................................................... 14 Core Decompression for Avascular Necrosis - Effective Oct. 1, 2015 ..................................................................................................................... 15 Diagnostic (Basic) Procedures for Infertility - Effective Oct. 1, 2015 ...................................................................................................................... 16 Embolization of the Ovarian and Iliac Veins for Pelvic Congestion Syndrome - Effective Oct. 1, 2015 ........................................................................ 17 Lithotripsy for Salivary Stones - Effective Oct. 1, 2015 ........................................................................................................................................ 17 Mifeprex (Mifepristone, RU-486) - Effective Oct. 1, 2015 ..................................................................................................................................... 18 Nerve Graft to Restore Erectile Function During Radical Prostatectomy - Effective Oct. 1, 2015 ................................................................................ 19 Presacral Neurectomy and Uterine Nerve Ablation for Pelvic Pain - Effective Oct. 1, 2015 ........................................................................................ 19 Repository Corticotropin Injection (H.P. Acthar Gel) - Effective Nov. 1, 2015.......................................................................................................... 20 Rituxan (Rituximab) - Effective Nov. 1, 2015 ..................................................................................................................................................... 21 Routine Foot Care - Effective Oct. 1, 2015 ......................................................................................................................................................... 23 Sandostatin Lar Depot (Octreotide Acetate) - Effective Nov. 1, 2015 ..................................................................................................................... 23 Total Artificial Heart - Effective Oct. 1, 2015 ...................................................................................................................................................... 25 Transcutaneous Electrical Nerve Stimulation (TENS) for the Treatment of Nausea and Vomiting - Effective Oct. 1, 2015 ............................................. 26 Treatment of Infertility - Effective Oct. 1, 2015 .................................................................................................................................................. 26 Treatment of Infertility for Connecticut Groups - Effective Oct. 1, 2015 ................................................................................................................. 29 Treatment of Infertility for New Jersey Large Groups - Effective Oct. 1, 2015 ......................................................................................................... 31 Treatment of Infertility for New York Large and Small Groups - Effective Oct. 1, 2015............................................................................................. 34 Unicondylar Spacer Devices for Treatment of Pain or Disability - Effective Oct. 1, 2015 ........................................................................................... 36 Vaccines - Effective Oct. 1, 2015 ...................................................................................................................................................................... 37 Xolair (Omalizumab) - Effective Nov. 1, 2015 ..................................................................................................................................................... 37 REVISED Abnormal Uterine Bleeding and Uterine Fibroids - Effective Nov. 1, 2015 ............................................................................................................... 40 Botulinum Toxins A and B - Effective Nov. 1, 2015 ............................................................................................................................................. 42 Clotting Factors and Coagulant Blood Products - Effective Nov. 1, 2015 ................................................................................................................. 48 Drug Coverage Criteria - New and Therapeutic Equivalent Medications - Effective Nov. 1, 2015 ................................................................................ 49 3 Oxford® Policy Update Bulletin: October 2015 Oxford Oxford® Medical and Administrative Policy Updates In This Issue Drug Coverage Guidelines - Effective Sep. 10, 2015 ........................................................................................................................................... 49 o Praluent (Alirocumab) ...............................................................................................................................................................................
Load more

Recommended publications
  • A Study of Bioethical Qualifiers in the Donation of Human Sperm
    Intersect, Vol 14, No 2 (2021) Creating Boundaries in the Sperm Donation Industry: A Study of Bioethical Qualifiers in the Donation of Human Sperm Tanvee Sinha1 1 The University of Alabama at Birmingham While sperm donation has become a common and effective practice amongst many who suffer from the inability to conceive naturally, the practice's bioethical implications may reveal a necessity to place qualifying constrictions on the practice. Some examples of related ethical issues range from psychological impacts on offspring as a result of partial genetic dissociation from parents, and discriminatory practices, such as “shopping” for traits or narrow descriptions of optimal sperm donors. Regulations for eligible donors vary in different regions, while keeping some sort of uniformity through criteria, including height, weight, education, and lifestyle choices. This piece highlights some of the major cultural differences between China and the USA in regard to the regulation of sperm donation. Recently in China, after the “one- child only” policy was lifted, there is an increasing demand for sperm donors now than ever, but with new policies, it is even more difficult to donate and purchase sperm. Due to donors not being able to qualify for the “amount of patriotism” needed, there is an increased use of underground operations, such as the black market. These operations are often unsafe and have no regulation, encouraged by donors and middlemen solely seeking monetary value. Sinha, Boundaries in Sperm Donation Background In the twentieth century, there has been a rapid advancement in technology, causing numerous innovative ways for one to now have a child.
    [Show full text]
  • Regulating Egg Donation: a Comparative Analysis of Reproductive Technologies in the United States and United Kingdom
    FOUR REGULATING EGG DONATION: A COMPARATIVE ANALYSIS OF REPRODUCTIVE TECHNOLOGIES IN THE UNITED STATES AND UNITED KINGDOM Michelle Sargent While rapid scientific development of egg donation technology has made it possible to elude infertility and to expand options for means of procreation, it has also thrust policy makers advanced societies in the midst of a raging debate that involves several ethical concerns. This paper describes and contrasts the respective regulatory approaches of the United States and the United Kingdom towards egg donation, and explores their potential implications for policy making in both countries. Michelle Sargent is currently pursuing her masters at the Gerald R. Ford School of Public Policy at the University of Michigan, with a concentration in energy, climate change, and environmental policy. Prior to returning to school to pursue her masters, Ms. Sargent worked at an environmental consulting firm on several different projects, including a new business model to reduce chemical usage and hazardous waste in chemical manufacturing firms, and a philanthropic collaborative to promote sustainable food systems in California. She also coordinated grant administration to small Latino nonprofits with a foundation affinity group. Ms. Sargent was named a Morris K. Udall scholar in environment in 2000 and received her Bachelor of Arts from Vassar College. Michigan Journal of Public Affairs – Volume 4, Spring 2007 The Gerald R. Ford School of Public Policy – The University of Michigan, Ann Arbor www.mjpa.umich.edu Regulating Egg Donation: A Comparative Analysis 2 INTRODUCTION Procreation is a fundamental human drive. The image of happy parents holding a healthy baby pervades our society, from Gerber commercials to TV sitcoms.
    [Show full text]
  • What Women Want in Their Sperm Donor: a Study of More Than 1000
    Economics and Human Biology 23 (2016) 1–9 Contents lists available at ScienceDirect Economics and Human Biology journa l homepage: www.elsevier.com/locate/ehb What women want in their sperm donor: A study of more than 1000 women’s sperm donor selections a, b c Stephen Whyte *, Benno Torgler , Keith L. Harrison a School of Economics and Finance, Queensland University of Technology, Gardens Point, 2 George St., Brisbane, QLD 4001, Australia b School of Economics and Finance, Queensland University of Technology, Gardens Point, 2 George St, Brisbane, QLD 4001, Australia; and CREMA—Center for Research in Economics, Management and the Arts, Switzerland c Queensland Fertility Group (QFG), Australia A R T I C L E I N F O A B S T R A C T Article history: Received 28 March 2016 Reproductive medicine and commercial sperm banking have facilitated an evolutionary shift in how Received in revised form 24 May 2016 women are able to choose who fathers their offspring, by notionally expanding women’s opportunity set Accepted 12 June 2016 beyond former constraints. This study analyses 1546 individual reservations of semen by women from a Available online 16 June 2016 private Australian assisted reproductive health facility across a ten year period from 2006 to 2015. Using the time that each sample was available at the facility until reservation, we explore women’s preference JEL classification: for particular male characteristics. We find that younger donors, and those who hold a higher formal J13 education compared to those with no academic qualifications are more quickly selected for reservation D10 by women.
    [Show full text]
  • Building Your Family at Northwestern Medicine Fertility and Reproductive Medicine Northwestern Medicine Building Your Family
    Building Your Family at Northwestern Medicine Fertility and Reproductive Medicine Northwestern Medicine Building Your Family Building your family Northwestern Medicine Fertility and Reproductive Medicine takes pride in helping all individuals and couples build their families. Procreation is a natural desire for many individuals and our faculty and staff provide an inclusive and supportive environment to all of our patients undergoing fertility treatment. We understand that family building can be an emotional and sometimes stressful process and we will be there to help guide you on your path to parenthood. We are a successful fertility program offering comprehensive services in downtown Chicago. Our There are many paths to parenthood for same-sex physicians, and other members of our team, are sensitive couples. We offer a full array of family-building strategies, to patient’s goals and needs, and steadfast in our support including artificial insemination, in vitro fertilization, egg of all of our patients. We will help you fulfill your family and sperm donation, and gestational surrogacy. building dreams. Visit womenshealthcommunity.nm.org to share your stories and ask a fertility question from one of our medical experts. 2 Northwestern Medicine Building Your Family Reproductive options Options for lesbian women/couples partner’s eggs to create embryos to be fertilized with Lesbian women/couples may undergo treatment with donor sperm and then transferred into the other partner’s artificial insemination (Intrauterine Insemination; IUI), uterus. using sperm from a known donor or from a sperm donor identified through a sperm bank. IUI is a relatively simple Options for gay men/couples and painless treatment that is either performed with or Gay men/couples may choose to work with a gestational without the patient taking hormone medications.
    [Show full text]
  • 150 Half-Siblings? Sperm Donation Creates Superfamilies by Madeleine White
    September 6, 2011 150 half-siblings? Sperm donation creates superfamilies By Madeleine White Critics say sperm banks need to be regulated to prevent accidental incest and a shrinking gene pool Imagine telling a child that she is the product of a sperm donor. Now imagine telling her that, also, she has up to 150 siblings. A piece in The New York Times [http://www.nytimes.com/2011/09/06/health/06donor.html? _r=1&pagewanted=all&src=ismr_ap_lo_mst_fb] examines the growing trend of half-siblings across the United States as sperm banks dole out copious amounts of samples from the same, popular donors. Not only does this cause concerns for scientists – who worry about a shrinking gene pool and the possibility of unnatural propagation of rare genetic disorders – but also for parents who suddenly realize that their family has grown exponentially. One unforeseen consequence is that accidental incest is a real possibility. One mother has informed her daughter of her donor's number in case the girl ever decides to become intimate with another sperm-donor child. "She's been in school with numerous kids who were born through donors. She's had crushes on boys who are donor children. It's become part of [her]sex education," the unnamed California mom said. Critics [http://feministing.com/2011/09/06/should-artificial-insemination-be-regulated] see this as one of many reasons why sperm banks need to be regulated legally. (In Canada there is some regulation [http://www.ahrc-pac.gc.ca/v2/index-eng.php], including a national registry of personal health information
    [Show full text]
  • Should the U.S. Approve Mitochondrial Replacement Therapy?
    SHOULD THE U.S. APPROVE MITOCHONDRIAL REPLACEMENT THERAPY? An Interactive Qualifying Project Report Submitted to the Faculty of WORCESTER POLYTECHNIC INSTITUTE In partial fulfillment of the requirements for the Degree of Bachelor of Science By: ____________________ ____________________ ____________________ Daniela Barbery Emily Caron Daniel Eckler IQP-43-DSA-6594 IQP-43-DSA-7057 IQP-43-DSA-5020 ____________________ ____________________ Benjamin Grondin Maureen Hester IQP-43-DSA-5487 IQP-43-DSA-2887 August 27, 2015 APPROVED: _________________________ Prof. David S. Adams, PhD WPI Project Advisor 1 ABSTRACT The overall goal of this project was to document and evaluate the new technology of mitochondrial replacement therapy (MRT), and to assess its technical, ethical, and legal problems to help determine whether MRT should be approved in the U.S. We performed a review of the current research literature and conducted interviews with academic researchers, in vitro fertility experts, and bioethicists. Based on the research performed for this project, our team’s overall recommendation is that the FDA approve MRT initially for a small number of patients, and follow their offspring’s progress closely for a few years before allowing the procedure to be done on a large scale. We recommend the FDA approve MRT only for treating mitochondrial disease, and recommend assigning parental rights only to the two nuclear donors. In medical research, animal models are useful but imperfect, and in vitro cell studies cannot provide information on long-term side-effects, so sometimes we just need to move forward with closely monitored human experiments. 2 TABLE OF CONTENTS Title Page ……………………………….……………………………………..……. 01 Abstract …………………………………………………………………..…………. 02 Table of Contents ………………………………………………………………..… 03 Acknowledgements …………………………………………………………..…….
    [Show full text]
  • Making Sense of Donors and Donor Siblings: a Comparison of the Perceptions of Donor-Conceived Offspring in Lesbian- Parent and Heterosexual-Parent Families
    Making Sense of Donors and Donor Siblings: A Comparison of the Perceptions of Donor-Conceived Offspring in Lesbian- Parent and Heterosexual-Parent Families Submitted to Contemporary Perspectives in Family Research, Volume 13, Theme: “Visions of the 21st Century Family: Transforming Structures and Identities.” Eds. S. L. Blair and P. N. Claster Emerald Group Publishing Limited (in press, 2013) Margaret K. Nelson Department of Sociology and Anthropology Middlebury College Middlebury, VT 05753 U.S.A. [email protected] Rosanna Hertz Wellesley College Department of Sociology Wellesley, MA 02481 U.S.A. [email protected] Wendy Kramer Donor Sibling Registry Box 1571 Nederland, CO 80466 U.S.A. [email protected] NOTICE: This is the author’s version of a work that was accepted for publication. Changes resulting from the publishing process, such as editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. Please contact the authors for the final version. 1 MAKING SENSE OF DONORS AND DONOR SIBLINGS: A COMPARISON OF THE PERCEPTIONS OF DONOR-CONCEIVED OFFSPRING IN LESBIAN-PARENT AND HETEROSEXUAL-PARENT FAMILIES Margaret K. Nelson, Rosanna Hertz, and Wendy Kramer1 For most heterosexual families baby making has been an easy and often accidental occurrence. Yet, this is not the case for all heterosexual families; nor, of course is it the case for new forms of family headed by single mothers by choice, lesbians and gay men (Sullivan, 2004; Hertz, 2006, Gamson, 2011). Across the spectrum of family types, individuals – both alone and as members of couples – have turned to many different approaches to having a child.
    [Show full text]
  • Sperm Donor Catalog Fall 2014 – Winter 2015 Table of Contents This Catalog Provides Basic Information and Characteristics for Our Qualified Donors
    Sperm Donor Catalog Fall 2014 – Winter 2015 Table of Contents This catalog provides basic information and characteristics for our qualified donors. Please consider it a general guide rather than a list of available vials, as donors are regularly added to and retired from our roster. Additional information including regularly updated vial availability can be found at europeanspermbankusa.com » Getting Started 4 Donor Information & Availability Open ID Donors Specimen Types 5 » Access Pass » Quality at ESB-USA 6 IUI (motile cells) & ICI (motile cells) & cost » Shipping Comparison 7 12 » What is CMV? Why is this important regarding pregnancy? 8 » Profiles to Pregnancy: Your Guide to Purchasing Vials How does this affect my donor sperm choice? Find and Purchase Information on Your Favorite Donors What type of CMV testing do sperm donors go through? Fill Out Related Paperwork | Place Your Order for Donor Sperm . Specializing in Open Identity Donors Vial Exchange & Buy Back Program 14 » 9 » What is an Open ID Donor? Donor Sperm Definitions, Preparation Methods and Vial Types What does this mean for your child? Consult Your Physician | Demystifying Methods of Insemination What does this mean for your donor? 10 » Insemination Methods–Explained » Donor Process Home Insemination | IVF 16 » Donor Screening 18 Initially our donors are selected based on parameters 35 » More Ways to Save 36 » Accreditations & Licenses » Tell Us Your News 38 Reporting your pregnancy 39 » Testimonials What is CMV? Why is this important regarding pregnancy? How does this affect my donor sperm choice? What type of CMV testing do sperm donors go through? Specializing in Open Identity Donors What is an Open ID Donor? What does this mean for your child? What does this mean for your donor? Donor Process Donor Screening Initially our donors are selected based on parameters More Ways to Save Accreditations & Licenses Tell Us Your News Reporting your pregnancy Testimonials Getting Started Donor Information Open ID Donors European Sperm Bank USA offers extensive information on our donors.
    [Show full text]
  • Sperm Donation in Israel
    הכנסת The Knesset מרכז מחקר ומידע RESEARCH AND INFORMATION CENTRE Background Paper on Sperm Donation in Israel Presented to the Committee on the Rights of the Child Written by: Naomi Mei-Ami, Research & Information Staff March 2005 Authorization: Shmulik Hiskiya, Team Leader Translated by: Foreign Languages Dept. 1. Introduction This document was prepared for a debate held by the Knesset Committee on the Rights of the Child about sperm donation in Israel. The document provides a survey of the following topics: 1. Data on sperm donation in Israel; 2. Changes in conditions for receiving a sperm donation; 3. Changes in the composition of the population requiring sperm donation in Israel; 4. Ministry of Health regulations for management of a sperm bank; 5. Management of a central information base and preservation of donor anonymity – arguments for and against; 6. The emotional implications on the child of being conceived through sperm donation; 7. The right to parenthood vs. the welfare of the child; 8. Legal aspects of sperm donation; 9. An international comparison of legislation on the issue. 2. Background The use of sperm from a donor began as a solution to fertility problems of couples due to infertility of the male partner. Sperm donation can be used in two ways: injection of the sperm directly into the uterus (Artificial insemination); or In Vitro Fertilization (IVF), fertilization of ova outside of the body followed by the placement of the fertilized ova in the woman’s uterus. In 1988, artificial insemination by a donor (AID) was permitted for unmarried women, however, until 1997, they were discriminated against in regard to sperm donation.
    [Show full text]
  • Commentary USP 40–NF 35
    Commentary USP 40–NF 35 November 1, 2016 In accordance with USP’s Rules and Procedures of the Council of Experts (“Rules”) and except as provided in Section 7.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be re-published in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without re-publication in PF, a summary of comments received and the appropriate Expert Committee's responses are published in the Revisions and Commentary section of the USP website at the time the official revision is published. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail. For further information, contact: USP Executive Secretariat United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 USA [email protected] Page 1
    [Show full text]
  • Reproductive Dreams and Nightmares: Sperm Donation in the Age of At-Home Genetic Testing
    Loyola University Chicago Law Journal Volume 51 Issue 3 Spring 2020 Article 5 2020 Reproductive Dreams and Nightmares: Sperm Donation in the Age of At-Home Genetic Testing Nofar Yakovi Gan-Or Follow this and additional works at: https://lawecommons.luc.edu/luclj Part of the Law Commons Recommended Citation Nofar Yakovi Gan-Or, Reproductive Dreams and Nightmares: Sperm Donation in the Age of At-Home Genetic Testing, 51 Loy. U. Chi. L. J. 791 (). Available at: https://lawecommons.luc.edu/luclj/vol51/iss3/5 This Article is brought to you for free and open access by LAW eCommons. It has been accepted for inclusion in Loyola University Chicago Law Journal by an authorized editor of LAW eCommons. For more information, please contact [email protected]. Reproductive Dreams and Nightmares: Sperm Donation in the Age of At-Home Genetic Testing Nofar Yakovi Gan-Or* Recent technological developments surrounding genetic testing pose new challenges to well-established reproductive practices. One current example is the fertility industry’s struggle to maintain gamete donor anonymity against the growing use of direct-to-consumer DNA tests. Consider the widely covered story of Danielle Teuscher, who in 2019 accidentally discovered the identity of her daughter’s anonymous sperm donor after using a 23andMe DNA test. Danielle’s attempt to reach out to the newfound family member was followed by a cease and desist letter from the sperm bank for violating their agreement. In addition, the sperm bank refused to give Danielle the four vials of sperm from the same donor, which she had reserved for future use, thus thwarting her reproductive plans to have genetic siblings for her daughter.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Washington, D.C
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended March 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission File Number: 1-15182 DR. REDDY’S LABORATORIES LIMITED (Exact name of Registrant as specified in its charter) Not Applicable TELANGANA, INDIA (Translation of Registrant’s name (Jurisdiction of incorporation or into English) organization) 8-2-337, Road No. 3, Banjara Hills Hyderabad, Telangana 500 034, India +91-40-49002900 (Address of principal executive offices) Saumen Chakraborty, Chief Financial Officer, +91-40-49002004, [email protected] 8-2-337, Road No. 3, Banjara Hills, Hyderabad, Telangana 500 034, India (Name, telephone, e-mail and/or facsimile number and address of company contact person) Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of Each Class Name of Each Exchange on which Registered American depositary shares, each New York Stock Exchange representing one equity share Equity Shares* * Not for trading, but only in connection with the registration of American depositary shares, pursuant to the requirements of the Securities and Exchange Commission.
    [Show full text]